# Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

> **NCT00016107** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 72 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** estramustine phosphate sodium
- **DRUG:** docetaxel
- **BIOLOGICAL:** bevacizumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00016107
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2007-02
- **Final completion:** —
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00016107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00016107, "Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00016107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*